TY  - JOUR
AU  - Reck, M
AU  - Ciuleanu, T-E
AU  - Cobo, M
AU  - Schenker, M
AU  - Zurawski, B
AU  - Menezes, J
AU  - Richardet, E
AU  - Bennouna, J
AU  - Felip, E
AU  - Juan-Vidal, O
AU  - Alexandru, A
AU  - Sakai, H
AU  - Lingua, A
AU  - Reyes, F
AU  - Souquet, P-J
AU  - De Marchi, P
AU  - Martin, C
AU  - Pérol, M
AU  - Scherpereel, A
AU  - Lu, S
AU  - Paz-Ares, L
AU  - Carbone, D P
AU  - Memaj, A
AU  - Marimuthu, S
AU  - Zhang, X
AU  - Tran, P
AU  - John, T
PY  - 2021
DO  - 10.1016/j.esmoop.2021.100273
UR  - https://hdl.handle.net/10668/26943
T2  - ESMO open
AB  - To further characterize survival benefit with first-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone, we report updated data from the phase III CheckMate 9LA trial with a 2-year minimum follow-up. Adult patients...
LA  - en
KW  - NSCLC
KW  - dual immunotherapy
KW  - first-line
KW  - ipilimumab
KW  - nivolumab
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Humans
KW  - Ipilimumab
KW  - Lung Neoplasms
KW  - Neoplasm Recurrence, Local
KW  - Nivolumab
TI  - First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.
TY  - research article
VL  - 6
ER  -